Rosemina Merchant
Founder bei MEDICENNA THERAPEUTICS CORP.
Vermögen: 7 Mio $ am 31.03.2024
Profil
Rosemina Merchant was the founder of Intelligene Expressions, Inc. (founded in 1992) where she held the title of Chief Operating Officer & VP-Manufacturing from 1992 to 2002.
She is also the founder of Medicenna Therapeutics, Inc. (founded in 2011) where she currently holds the title of Director.
Additionally, she is the founder of Medicenna Therapeutics Corp.
(founded in 2011) where she currently holds the title of Chief Development Officer.
Ms. Merchant's current job is as Vice President-International Regulatory Affairs at Intelligenetics, Inc. (since 2001).
Her former job was as Vice President-Regulatory Affairs & Development at Sophiris Bio, Inc. (from 2004 to 2013).
Merchant has a graduate degree from the University of Western Ontario and an undergraduate degree from the University of Aston.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2023 | 5 300 700 ( 7,61% ) | 7 Mio $ | 31.03.2024 |
Aktive Positionen von Rosemina Merchant
| Unternehmen | Position | Beginn |
|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Founder | 01.10.2011 |
Intelligenetics, Inc.
 Intelligenetics, Inc. Information Technology ServicesTechnology Services Intelligenetics, Inc. engages in the provision of bioinformatics services. The company is headquartered in Campbell, CA. | General Counsel | 01.01.2001 |
Medicenna Therapeutics, Inc.
 Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Founder | 30.10.2011 |
Ehemalige bekannte Positionen von Rosemina Merchant
| Unternehmen | Position | Ende |
|---|---|---|
| SOPHIRIS BIO | General Counsel | 01.01.2013 |
| Intelligene Expressions, Inc. | Founder | 01.01.2002 |
Ausbildung von Rosemina Merchant
| University of Western Ontario | Graduate Degree |
| University of Aston | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
Intelligenetics, Inc.
Intelligenetics, Inc. Information Technology ServicesTechnology Services Intelligenetics, Inc. engages in the provision of bioinformatics services. The company is headquartered in Campbell, CA. | Technology Services |
| Intelligene Expressions, Inc. | |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Health Technology |
